Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Paclitaxel in Advanced Biliary Tract Cancer
NCT05170438Phase 2Active, not recruiting
- Sponsor
- National Health Research Institutes
- Start
- Jul 2022
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and Paclitaxel Micelles for Injection in biliary tract cancer (BTC), sponsored by National Health Research Institutes. Primary endpoint: Overall Response Rate at 2 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
lenvatinibPaclitaxel Micelles for Injection
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05170438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170438.